Vanda Pharmaceuticals | VNDA - Cash And Equivalent


Vanda Pharmaceuticals reported $84.85M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 819.69M 27.33M Dec/2025
Agios Pharmaceuticals USD 89.13M 3.58M Dec/2025
Akebia Therapeutics USD 184.84M 18.4M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Anika Therapeutics USD 57.99M 4.82M Sep/2025
Arrowhead Research USD 201.64M 112.94M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Esperion Therapeutics USD 92.45M 6.39M Sep/2025
Halozyme Therapeutics USD 133.82M 285.84M Dec/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Insmed USD 510.44M 175.68M Dec/2025
J&J USD 19.71B 1.48B Dec/2025
Lexicon Pharmaceuticals USD 21.36M 41.52M Jun/2025
Ligand Pharmaceuticals USD 174.93M 489.59M Dec/2025
Merck USD 18.17B 10.16B Sep/2025
Minerva Neurosciences USD 12.29M 2.96M Sep/2025
Moderna USD 2.6B 1.46B Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Takeda JPY 654.94B 26.55B Dec/2025
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025
Veracyte USD 362.58M 47M Dec/2025